close
close

topicnews · July 17, 2025

Asian Penny is seeing in July 2025

Asian Penny is seeing in July 2025

In the middle of a background steamed market reactions on new US tariffs and mixed economic signals from large economies, Asian markets navigate in a complex landscape in July 2025. While global attention is often on large cap shares, penny shares concentrates-an outdated term of office acts a fascinating segment for investors who are looking for growth opportunities at cheaper prices. These smaller or newer companies can offer considerable potential if they are based on solid financial data, and in this article three such promising penny shares in Asia are highlighted, which combine the balance sheet strength with the potential for impressive returns.

name

Stock price

Market capitalization

Financial health rating

JBM (healthcare) (Sehk: 2161)

HK $ 3.02

HK $ 2.46b

★★★★earch

Lever style (Sehk: 1346)

HK $ 1.39

HK $ 877.02 m

★★★★earch

Ever Sunshine Services Group (Sehk: 1995)

HK $ 2.11

HK $ 3.65b

★★★★★ ☆

TK group (Holdings) (Sehk: 2283)

HK $ 2.18

HK $ 1.82b

★★★★earch

CNMC Goldmine Holdings (Catalist: 5TP)

SGD0.445

SGD180.35m

★★★★★ ☆

TAC consumer (Set: TACC)

THB4.58

THB2.75b

★★★★earch

China Sunsine Chemical Holdings (SGX: Qes)

SGD0.635

SGD605.4m

★★★★earch

Yangzijiang Shipbuilding (Holdings) (SGX: BS6)

SGD2.35

SGD9.25b

★★★★★ ☆

Ekarat Engineering (Set: AKR)

THB0.93

THB1.37B

★★★★earch

Beng Kuang Marine (SGX: Bez)

SGD0.23

SGD46.51m

★★★★earch

Click here to display the full list of 976 shares from our Asian Penny Stocks Screener.

Here we emphasize a sub -group of our preferred stocks from the screen.

Simply Wall ST Financial Health Rating: ★★★★earch

Overview: The Lifetech Scientific Corporation is an investment holding company that develops and acts interventional medical devices for cardiovascular and peripheral vascular diseases on the Chinese mainland and various international markets with a market capitalization of 8.43 billion HK $.

Operations: The income of the company mainly comes from three segments: structural diseases (527.58 million yen), periphery vessel diseases (CN ¥ 751.11 million) as well as heart stimates and electrophysiology (CN 25.01 million).

Market capitalization: HK $ 8.43b

Lifetech Scientific recently strengthened its product portfolio by approving its innovative aortic arches and improved its position in the field of peripheral vascular interventions. The company is debt -free and short -term assets about the liabilities, which indicates solid financial health. However, there are challenges such as negative profit growth in the past year and a small return on equity of 4.8%. Despite stable weekly volatility and high -quality profits, profit margins have decreased from 20.8% to 17.1%. The recent appointment of the board can bring new perspectives to effectively control these challenges.